# Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

> **NCT05981235** · PHASE1 · COMPLETED · sponsor: **Peking University** · enrollment: 8 (actual)

## Conditions studied

- Gastrointestinal Tumors

## Interventions

- **BIOLOGICAL:** AZD6422 CLDN18.2 CAR-T product

## Key facts

- **NCT ID:** NCT05981235
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-14
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05981235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05981235, "Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05981235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*